Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision

03 | General Hospital Company

Hikaru Samejima, President

Safe Harbor for Forward-Looking Statements and Use of Document

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

The market share information in this presentation is partly derived from our own independent research.

Information about products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

Terumo Corporation

Investor Relations Dept.

E-mail: kouhou_terumo01@terumo.co.jp

©TERUMO CORPORATION

2 / 17

Vision for our 5-Year Growth Strategy

We provide patient centered solutions that integrate our unique technologies, contributing to the advancement of high quality, innovative medical care.

©TERUMO CORPORATION

3 / 17

Our Core Competencies

Diabetes (insulin delivery) solutions

Drug delivery solutions for pharmaceutical companies

(DM & consumer health care)

(Alliance)

IV drug delivery solutions

Peritoneal dialysis solutions

(General hospital products)

(Pharmaceutical)

Medical

safety,

efficiency

Drug delivery technologies

drug, device, ME, digital, cannula

©TERUMO CORPORATION

4 / 17

Looking Back on Current Mid- to Long-term Growth Strategy

Summary of current mid- to long-term growth strategy

Achievements

Adjusted operating profit %

16.8% 16.2%

Enhanced product portfolio by focusing on the diabetes treatment field

Acquired big projects from pharmaceutical companies

15.5%

14.8% 14.7%

Areas identified for further improvement:

  • Handing price pressures from drug and reimbursement price reductions, group purchasing, etc.
  • Expanding business more globally
  • Building a more optimal operational structure

GS26 Direction

  • Shift DM and Alliance (pharmaceutical solutions) businesses to growth pillars
  • Develop solutions by leveraging digital technologies, shifting to new business models, and transforming Japan sales style
  • Acquire a bridgehead for global business
  • Optimize global operations

Revenue (B JPY)

158 159 166 171 176

FY16

FY17

FY18

FY19

FY20 FY21Est.

©TERUMO CORPORATION

5 / 17

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Terumo Corporation published this content on 16 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 December 2021 08:58:06 UTC.